About the Book
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Pages: 44. Chapters: EC 2.7.10, Tyrosine kinase inhibitors, Tyrosine kinase receptors, Janus kinase, Imatinib, C-Met, Epidermal growth factor receptor, Abl gene, Insulin-like growth factor 1 receptor, LYN, Sunitinib, Tyrosine kinase 2, CD117, Lck, HER2/neu, Trk receptor, RET proto-oncogene, Insulin receptor, Erlotinib, TrkA receptor, TrkB receptor, Receptor tyrosine kinase, Syk, ZAP70, ERBB3, Lapatinib, Fibroblast growth factor receptor 2, Gefitinib, TrkC receptor, Crizotinib, Fibroblast growth factor receptor 3, Dasatinib, CD135, C-src tyrosine kinase, Kinase insert domain receptor, Vatalanib, Tyrosine-kinase inhibitor, ROR1, Semaxanib, CP-868,596, VEGF receptors, Nilotinib, Vandetanib, MuSK protein, Tofacitinib, Cediranib, Neratinib, Axitinib, Lestaurtinib, Toceranib, Ruxolitinib, Bosutinib, Non-receptor tyrosine kinase, TIE1, Damnacanthal, Angiopoietin receptor, Receptor tyrosine kinase-like orphan receptor, Tir, Quizartinib, Regorafenib, RTK class III, Ephrin. Excerpt: c-Met (MET or MNNG HOS Transforming gene) is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR). The hepatocyte growth factor receptor protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. MET is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the MET receptor. MET is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, MET induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal MET activation in cancer correlates with poor prognosis, w...
